ZOFAPANTM
Route of administration
Intravenous
Composition – Each Combi Pack contains:
A. Pantoprazole for Injection
Each vial contains:
Pantoprazole Sodium IP
equivalent to Pantoprazole…40 mg
B. (For Reconstitution)
Each FFS Ampoule contains:
Each FFS Ampoule contains:
Sodium Chloride Injection IP (0.9% w/v) 10 mL
INDICATIONS
Pantoprazole for Injection BP is indicated for short-term treatment (7 to 10 days) of patients with conditions where a rapid reduction of gastric acid secretion is required, such as the following:
Reflux esophagitis
Gastric and duodenal ulcer
Zollinger – Ellison Syndrome and other pathological hypersecretory conditions.
It is an alternative in patients for whom oral administration of Pantoprazole is not indicated.
ZOFASOMⓇ
Route of administration
Intravenous
Composition – Each Combi Pack contains:
A. Esomeprazole Sodium for Injection
Each vial contains:
Esomeprazole Sodium Ph. Eur.
equivalent to Esomeprazole……….40 mg
B. (For Reconstitution)
Each FFS Ampoule contains:
Sodium Chloride Injection IP (0.9% w/v) 5 mL
INDICATIONS
Esomeprazole sodium for injection and infusion is indicated in adults for:
Gastric antisecretory treatment when the oral route is not possible, such as:
gastroesophageal refux disease (GERD) in patients with esophagitis and/or severe symptoms of refux.
healing of gastric ulcers associated with NSAID therapy.
prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.
Prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers.
Esomeprazole sodium for injection and infusion is indicated in children and adolescents aged 1-18 years for:
Gastric antisecretory treatment when the oral route is not possible, such as:
gastroesophageal refux disease (GERD) in patients with erosive refux esophagitis and/or severe symptoms of refux
ZOFAMEZⓇ
Route of administration
Intravenous
Composition – Each Combi Pack contains:
A. Omeprazole for Injection
Each vial contains:
Omeprazole Sodium BP
equivalent to Omeprazole……..40 mg
B. (For Reconstitution)
Each FFS Ampoule contains:
Sterile Water for Injection IP 10 mL
INDICATIONS
As an alternative to oral therapy for the following indications:
Treatment of duodenal ulcers.
Prevention of relapse of duodenal ulcers.
Treatment of gastric ulcers.
Prevention of relapse of gastric ulcers.
In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic ulcer disease.
Treatment of NSAID-associated gastric and duodenal ulcers.
Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk.
Treatment of reflux esophagitis.
Long-term management of patients with healed reflux esophagitis.
Treatment of symptomatic gastro-esophageal reflux disease.
Treatment of Zollinger-Ellison syndrome.
ZOFARABⓇ
Route of administration
Intravenous
Composition – Each Combi Pack contains:
A. One vial of Rabeprazole Injection IP
Each vial contains:
Rabeprazole Sodium IP….20mg
B. (For Reconstitution)
Each FFS Ampoule contains:
Sterile Water for Injection IP 5 mL
INDICATIONS
It is alternative in patients for whom oral administration of Rabeprazole is not indicated. Rabeprazole
Injection IP is indicated in the treatment of:
Gastric and duodenal ulcer.
Gastroesophageal Reflux Disease (GERD).
As an alternative to oral therapy in patients who are unable to take proton-pump inhibitor.
Prevention of acid-aspiration.
Stress-induced mucosal injury in critical care.
Pathological hyper secretory conditions including Zollinger-Ellison syndrome.
KAIVEXIN® – 20/40/60/80
Route of administration
Subcutaneous / Intravascular
Composition – Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….20 mg
(Porcine Derived)
Equivalent to 2000 IU of Anti-factor Xa Activity
Water For Injections I.P………..q.s. to 0.2 mL
Composition – Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….40 mg
(Porcine Derived)
Equivalent to 4000 IU of Anti-factor Xa Activity
Water For Injections I.P………..q.s. to 0.4 mL
Composition – Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….60 mg
(Porcine Derived)
Equivalent to 6000 IU of Anti-factor Xa Activity
Water For Injections I.P………..q.s. to 0.6 mL
Composition – Each Pre-filled Syringe Contains:
Enoxaparin Sodium I.P..….80 mg
(Porcine Derived)
Equivalent to 8000 IU Anti-factor Xa Activity
Water For Injections I.P……….q.s. to 0.8 mL
INDICATIONS
The prophylaxis of thromboembolic disorders of venous origin, in particular those which may be associated with orthopaedic or general surgery.
The prophylaxis of venous thromboembolism in medical patients bedridden due to acute illnesses including cardiac insufficiency, respiratory failure, or severe infections.
The treatment of venous thromboembolic disease presenting with deep vein thrombosis, pulmonary embolism or both.
The treatment of unstable angina and non-Q-wave myocardial infarction administered concurrently with aspirin.
Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent
Percutaneous Coronary Intervention (PCI). The prevention of thrombus formation in the extracorporeal circulation during haemodialysis
KAIVEXINⓇ– 300
Route of administration
Subcutaneous
Composition – Each Multidose cartridge contains:
Enoxaparin Sodium I.P…….. 300 mg/3mL
(Porcine derived)
Phenol I.P…………………………..0.25% w/v
(As Preservative)
Water For Injections I.P…………………. q.s.
INDICATIONS
The prophylaxis of thromboembolic disorders of venous origin, in particular those which may be associated with orthopaedic or general surgery.
The prophylaxis of venous thromboembolism in medical patients bedridden due to acute illnesses including cardiac insufficiency, respiratory failure, or severe infections.
The treatment of venous thromboembolic disease presenting with deep vein thrombosis, pulmonary embolism or both.
The treatment of unstable angina and non-Q-wave myocardial infarction administered concurrently with aspirin.
Treatment of acute ST-segment Elevation Myocardial Infarction (STEMI) including patients to be managed medically or with subsequent Percutaneous Coronary Intervention (PCI). The pre-vention of thrombus formation in the extracorporeal circulation during haemodialysis.
